Premium
Dexpramipexole improves bioenergetics and outcome in experimental stroke
Author(s) -
Muzzi Mirko,
Gerace Elisabetta,
Buonvicino Daniela,
Coppi Elisabetta,
Resta Francesco,
Formentini Laura,
Zecchi Riccardo,
Tigli Laura,
Guasti Daniele,
Ferri Martina,
Camaioni Emidio,
Masi Alessio,
PellegriniGiampietro Domenico E,
Mannaioni Guido,
Bani Daniele,
Pugliese Anna M,
Chiarugi Alberto
Publication year - 2018
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13790
Subject(s) - neuroprotection , bioenergetics , penumbra , pharmacology , mitochondrion , hippocampal formation , medicine , ischemia , atp synthase , neuroscience , biology , anesthesia , chemistry , microbiology and biotechnology , biochemistry , enzyme
Dexpramipexole, a drug recently tested in patients with amyotrophic lateral sclerosis (ALS,) is able to bind F1Fo ATP synthase and increase mitochondrial ATP production. Here, we have investigated its effects on experimental ischaemic brain injury.